HK1204966A1 - Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder -3 - Google Patents

Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder -3

Info

Publication number
HK1204966A1
HK1204966A1 HK15105751.1A HK15105751A HK1204966A1 HK 1204966 A1 HK1204966 A1 HK 1204966A1 HK 15105751 A HK15105751 A HK 15105751A HK 1204966 A1 HK1204966 A1 HK 1204966A1
Authority
HK
Hong Kong
Prior art keywords
beta
combination
receptor antagonists
muscarinic receptor
overactive bladder
Prior art date
Application number
HK15105751.1A
Other languages
English (en)
Chinese (zh)
Inventor
Stephen Caltabiano
Eliot Ohlstein
Stewart Mccallum
Original Assignee
Altherx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altherx Inc filed Critical Altherx Inc
Publication of HK1204966A1 publication Critical patent/HK1204966A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15105751.1A 2012-02-09 2015-06-17 Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder -3 HK1204966A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261596893P 2012-02-09 2012-02-09
PCT/US2013/025285 WO2013119910A1 (fr) 2012-02-09 2013-02-08 Combinaison d'antagonistes des récepteurs muscariniques et d'agonistes de l'adrénorécepteur bêta -3 pour le traitement de la vessie hyperactive

Publications (1)

Publication Number Publication Date
HK1204966A1 true HK1204966A1 (en) 2015-12-11

Family

ID=48948043

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105751.1A HK1204966A1 (en) 2012-02-09 2015-06-17 Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder -3

Country Status (13)

Country Link
EP (1) EP2811989A1 (fr)
JP (1) JP2015509931A (fr)
KR (1) KR20150020160A (fr)
CN (1) CN104684549A (fr)
AR (1) AR089957A1 (fr)
AU (1) AU2013216864A1 (fr)
CA (1) CA2864173A1 (fr)
HK (1) HK1204966A1 (fr)
IL (1) IL234033A0 (fr)
PH (1) PH12014501814A1 (fr)
SG (1) SG11201404776PA (fr)
TW (1) TW201338772A (fr)
WO (1) WO2013119910A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL124473C (fr) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1424079A1 (fr) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
EP2141992A1 (fr) * 2007-03-29 2010-01-13 Merck & Co., Inc. Polythérapie pour le traitement de troubles urinaires du bas appareil
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
WO2011025690A1 (fr) 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Nouveaux agonistes de récepteurs adrénergiques bêta 3 dérivés de pyrrolidine
CN102638987A (zh) * 2009-10-07 2012-08-15 默沙东公司 使用β3肾上腺素能受体激动剂和抗毒蕈碱药剂的组合疗法

Also Published As

Publication number Publication date
KR20150020160A (ko) 2015-02-25
TW201338772A (zh) 2013-10-01
CA2864173A1 (fr) 2013-08-15
WO2013119910A1 (fr) 2013-08-15
PH12014501814A1 (en) 2014-11-24
AU2013216864A1 (en) 2014-09-11
SG11201404776PA (en) 2014-09-26
IL234033A0 (en) 2014-09-30
JP2015509931A (ja) 2015-04-02
AR089957A1 (es) 2014-10-01
CN104684549A (zh) 2015-06-03
EP2811989A1 (fr) 2014-12-17

Similar Documents

Publication Publication Date Title
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
HRP20180915T1 (hr) Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora
PL2928890T3 (pl) Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
SG10201506076TA (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
IL238665B (en) Compositions for the permanent hydrophilization of fibers made from polyolefin and use of these compositions
HK1216503A1 (zh) 用於經皮傳遞安非他命的組合物及方法
HK1204966A1 (en) Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder -3
HK1202859A1 (en) Anti -malarial agents
ZA201408094B (en) Anti-malarial agents
PL2682129T3 (pl) Kompozycje zawierające antagonistę receptora muskarynowego i bezwodną glukozę
PL2682103T3 (pl) Kompozycje zawierające antagonistę receptora muskarynowego i sorbitol
IL237150B (en) Preparations containing combinations of receptor antagonists and agonists
IL236442A0 (en) Seed coating methods using preparations with ryanodine receptor agonists
HK1202459A1 (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
RS55201B1 (sr) Antimalarijski agensi